Citation Impact
Citing Papers
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
2013 StandoutScience
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m 6 A-demethylation of NANOG mRNA
2016 StandoutNobel
The DNA-damage response in human biology and disease
2009 StandoutNature
Small-Molecule Inhibitors of the p53-MDM2 Interaction
2010
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
2005 StandoutNature
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
Development of a Panel of 15 Human Ovarian Cancer Xenografts for Drug Screening and Determination of the Role of the Glutathione Detoxification System
2000
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
2013 StandoutNature
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients
1989
Molecular mechanisms of drug resistance
2005
The DNA Damage Response Kinases DNA-dependent Protein Kinase (DNA-PK) and Ataxia Telangiectasia Mutated (ATM) Are Stimulated by Bulky Adduct-containing DNA
2011 StandoutNobel
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
2012
Polymer-drug conjugates: Recent development in clinical oncology
2008
Prodrug Strategies in Anticancer Chemotherapy
2007
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Structure of and kinetic channelling in bifunctional dihydrofolate reductase–thymidylate synthase
1994
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
DNA repair pathways as targets for cancer therapy
2008
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
2002 Standout
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
2011 StandoutNatureNobel
Individual patient data analysis to assess modifications to the RECIST criteria
2008
UCSF Chimera—A visualization system for exploratory research and analysis
2004 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Chemotherapy and the war on cancer
2005 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Dendrimer biocompatibility and toxicity
2005
Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
2005
Phase II study of iproplatin in advanced ovarian carcinoma.
1988
Karnofsky memorial lecture. Ode to methotrexate.
1993
A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation
2010
Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience
2014
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
1989
γH2AX and cancer
2008
Application of Nanotechnology in Cancer Therapy and Imaging
2008
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
Polymer Architecture and Drug Delivery
2006
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
1988
Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance
1999
DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis
2020 StandoutNatureNobel
The methotrexate story: A paradigm for development of cancer chemotherapeutic agents
1994
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Pairwise specificity and sequential binding in enzyme catalysis: thymidylate synthase
1990
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
2009
Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
2000
New platinum antitumor complexes
1993
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Intrinsic and Acquired Resistance to Methotrexate in Acute Leukemia
1996
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
In Situ Click Chemistry: Enzyme‐Generated Inhibitors of Carbonic Anhydrase II
2004 StandoutNobel
The dawning era of polymer therapeutics
2003 Standout
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
2005
Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
1991
Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining
2009
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
1990
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications
2004 StandoutNobel
Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase
2000
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
Classical Electrostatics in Biology and Chemistry
1995 StandoutScience
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination
2009 StandoutNobel
Targeting DNA‐Dependent Protein Kinase for Cancer Therapy
2017
Kinase-dependent structural role of DNA-PKcs during immunoglobulin class switch recombination
2018
Insertion of an intracisternal A particle within the 5'-regulatory region of a gene encoding folate-binding protein in L1210 leukemia cells in response to low folate selection. Association with increased protein expression.
1992 StandoutNobel
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
1997
Structure-Based Strategies for Drug Design and Discovery
1992 Science
Extending Survival with Chemotherapy in Metastatic Breast Cancer
2005
Designing polymer conjugates as lysosomotropic nanomedicines
2007
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis
1989
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
1999 Standout
Modeling of Poly(ADP-ribose)polymerase (PARP) Inhibitors. Docking of Ligands and Quantitative Structure−Activity Relationship Analysis
2001
The DNA-damage response: new molecular insights and new approaches to cancer therapy
2009
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
2000
Electrostatic Basis for Enzyme Catalysis
2006 StandoutNobel
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Simultaneous precise editing of multiple genes in human cells
2019 StandoutNobel
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
In Situ Selection of Lead Compounds by Click Chemistry: Target-Guided Optimization of Acetylcholinesterase Inhibitors
2005 StandoutNobel
Site-directed ligand discovery
2000
Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes
1999
An electrostatic highway
1994
Metal–Organic Frameworks in Biomedicine
2011 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
New Therapies for Ovarian Cancer
1992
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
2005
Ovarian trials at the Royal Marsden
1985
DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSα/hMutSβ ratio and reduces the efficiency of base–base mismatch repair
1997 StandoutNobel
Structure-based drug design (SBDD): Every structure tells a story...
1993
Works of A H Calvert being referenced
Cisplatin/carboplatin cross-resistance in ovarian cancer
1989
Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience
1995
Folate-based thymidylate synthase inhibitors as anticancer drugs
1995
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients
1996
Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction
2005
Thymidylate synthase: A target for anticancer drug design
1989
Structural basis for recognition of polyglutamyl folates by thymidylate synthase
1992
Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group
2005
Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid (CB3717), on human lymphoblastoid cells
1983
Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441
2006
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
2002
A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
2007
Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)
1998
Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
1990
2-AMINO-4-HYDROXY QUINAZOLINE ANALOGS OF FOLIC-ACID AS THYMIDYLATE SYNTHETASE INHIBITORS
1979
ALIMTATM in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
2000
Handbook of Anticancer Drug Development
2004
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
2005
Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
2002
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer
1988
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).
1987
A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice
1981
Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer
2001
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
1986
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
1991
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
1983